AN2 Therapeutics, Inc.
ANTX
$-0.07
Change (1 day)
$22.22
Year High
$0.87
Year Low
Categories
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
P/E ratio for AN2 Therapeutics, Inc. (ANTX)
P/E ratio as of 2023: -7.47
According to AN2 Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -7.47. At the end of 2022 the company had a P/E ratio of -4.46.
P/E ratio history for AN2 Therapeutics, Inc. from 2019 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -7.47 |
| 2022 | -4.46 |
| 2021 | -13.44 |
| 2020 | -21.22 |
| 2019 | -51.21 |